AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs

Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene. The post AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs appeared first on Investor's Business Daily.#azn #astrazeneca
Source: Reuters: Health - Category: Consumer Health News Source Type: news